United States Limb-Girdle Muscular Dystrophy Industry Intelligence Report Boom | Top Companies - Teva Pharmaceuticals USA, Inc., Pfizer Inc., Viatris Inc., Atamyo Therapeutics, Sarepta Therapeutics, Inc

DataM Intelligence has released an in-depth research report on "Limb-Girdle Muscular Dystrophy Market Size 2025". This report delivers power-packed insights into key growth drivers, market segmentation, regional trends, CAGR forecasts, revenue performance of top players, and emerging opportunities. Gain a 360° market perspective with detailed analysis on value, volume, and future development trends your ultimate guide to spotting high-impact opportunities and staying ahead in this dynamic market.

For example, Sarepta Therapeutics, Inc. is running Phase 3 clinical trials for its gene therapy Bidridistrogene Xeboparvovec targeting limb-girdle muscular dystrophy, with primary completion expected by January 2025 and the full study projected to conclude by 2029.

Additionally, ML Bio Solutions, Inc. is developing BBP-418 (Ribitol), currently in Phase 3 clinical trials, to assess its long-term safety and efficacy in limb-girdle muscular dystrophy patients, with completion expected by mid-2027.

In the U.S., organizations like the Muscular Dystrophy Association (MDA) provide healthcare access, support research, and offer expert care. MDA's Care Center Network serves thousands yearly with multidisciplinary care, clinical trials, and community support for muscular dystrophy, ALS, and other neuromuscular diseases.

FDA Approvals

No new full FDA approvals in the last three months; however, regulatory interactions around BBP-418 and Sarepta's gene therapy suggest pathways toward eventual approval.

Download Your Sample PDF Today and (Get Priority Access With a Corporate Email ID For Faster Delivery):- https://www.datamintelligence.com/download-sample/limb-girdle-muscular-dystrophy-market-?kb

News

BridgeBio Pharma completed enrollment for its Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9 patients, aiming to be the first approved therapy for this LGMD subtype.

Discussions with the FDA suggest potential for accelerated approval based on biomarker surrogate endpoint data, raising hopes for earlier patient access.

Sarepta Therapeutics reported positive safety data from its gene therapy SRP-9003 trial in LGMD patients and received FDA platform technology designation for its viral vector delivery system.

The FDA placed a clinical hold on Sarepta's gene therapy trials temporarily due to safety concerns related to patient deaths, undergoing review and risk assessmen

List of Top Key Players:

Horizon Therapeutics plc, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Viatris Inc., Atamyo Therapeutics, Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., ML Bio Solutions, Inc., Genethon and Edgewise Therapeutics among others.

Clinical Trials

Phase 3 FORTIFY trial for BBP-418 is ongoing, with topline data expected soon; it targets improvement of muscle function by correcting glycosylation defects.

Multiple ongoing trials with gene therapies and stem cell transplantation are in progress across different LGMD subtypes, aiming to halt or reverse muscle degeneration.

A variety of observational and interventional studies are underway to monitor disease progression and evaluate novel therapeutic candidates globally.

Forecast Growth Projection:

Global Limb-Girdle Muscular Dystrophy Market Positioned for Strong Growth 2025-2032, Building on the steady momentum of 2024, the market is poised for remarkable expansion as leading players embrace innovative technologies and strategic advancements. This evolving landscape is unlocking lucrative opportunities for businesses to invest, scale, and stay ahead in an increasingly competitive and fast-moving market.

Market Research Process:

The Limb-Girdle Muscular Dystrophy Market research report by DataM Intelligence combines extensive Primary and Secondary research to provide powerful, in-depth insights. It examines key market drivers such as regulatory frameworks, evolving market conditions, competitive dynamics, historical trends, and breakthrough technologies, while spotlighting emerging innovations and potential challenges. This all-inclusive analysis uncovers high-growth opportunities and highlights possible barriers, equipping businesses to tackle market volatility and capture new avenues for success.

Buy Now & Get Instant Access to 360° Market Intelligence:- https://www.datamintelligence.com/research-report/limb-girdle-muscular-dystrophy-market-

Market Segments:

Physical therapy holds 34.2% of LGMD market share.

By Type: Limb-Girdle Muscular Dystrophy Type 1, Limb-Girdle Muscular Dystrophy Type 2

By Treatment Type: Physical Therapy, Medication, Occupational Therapy, Respiratory and Cardiac Care, Mobility Aids, Others

By End-Users: Hospitals & Clinics, Homecare, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Global Growth Regions:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Opens the report with a comprehensive market overview, highlighting key segments by region, product type, and application. It presents a clear snapshot of market size, growth potential by segment, and both short- and long-term outlook.

Chapter 2: Showcases the most impactful insights, uncovering the emerging trends and disruptive forces shaping the industry's future.

Chapter 3: Delivers an in-depth competitive landscape analysis of the Limb-Girdle Muscular Dystrophy market, covering revenue shares, strategic moves, and the latest mergers & acquisitions.

Chapter 4: Features detailed profiles of leading players, including their revenue streams, profit margins, product portfolios, and key milestones.

Chapters 5 & 6: Present a granular breakdown of regional and country-level revenue performance, offering a precise view of market size, opportunities, and development prospects worldwide.

Chapter 7: Analyzes market segmentation by product type, revealing the growth potential of each category and spotlighting high-impact.

Chapter 8: Examines application-based market growth, identifying the fastest-expanding sectors and lucrative opportunities for expansion.

Chapter 9: Maps the entire industry supply chain, providing insights into upstream and downstream activities for a complete market perspective.

Chapter 10: Concludes with key findings and actionable takeaways, guiding stakeholders toward strategic decisions and future growth opportunities.

Get Customization in the report as per your requirements:- https://www.datamintelligence.com/customize/limb-girdle-muscular-dystrophy-market-?kb

Q1: How Large is the Limb-Girdle Muscular Dystrophy Market?

A: The Limb-Girdle Muscular Dystrophy Market was valued at US$ 1.3 billion in 2023 and is expected to experience substantial growth, reaching US$ 2.4 billion by 2031.

Q2: How fast is the Limb-Girdle Muscular Dystrophy Market growing?

A: The Market is experiencing strong growth and is projected to expand at a CAGR of 7.4% from 2025 to 2032.

Q3: Which Region Leads Limb-Girdle Muscular Dystrophy Market growth?

A: North America is projected to lead the global LGMD market with a 41.3% share.

Try DataM Subscription Services free for 2 days - Get Started@ https://www.datamintelligence.com/reports-subscription?kb

Make smarter moves with real-time competitor insights, strategic forecasts, and global investment trends-get it all now!

Access your Subscription Dashboard today@ https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.